**Venue**

*Ergife Palace Hotel and Congress Centre*
Via Aurelia, 619
00165 Rome, Italy

**Language**

English is the official language of the Congress.
No simultaneous translation will be available.

**Continuing Medical Education**

The 5th EAHAD Congress has been recognized by EHA-CME Unit as CME event for Hematologists and will grant 9.5 credits to attending participants.

Accreditation for Italian Continuing Medical Education has also been obtained for the following specialties: haematology, medical genetics, internal medicine, pediatrics, orthopaedics, transfusion medicine, clinical pathology, biology, psychology, nursing sciences.

The number of Italian CME credits granted to participants attending the whole Congress is 7.5.

**Liability**

The Congress Organizers cannot accept liability for personal injuries sustained or for loss or damage to property belonging to Congress Participants, either during or as a result of the Congress. Please check the validity of your insurance.
THE ASSOCIATION

The European Association for Haemophilia and Allied Disorders is a multi-disciplinary association of healthcare professionals who provide care for individuals with haemophilia and other bleeding disorders. EAHAD purpose is to promote clinical care, education and research for this group of patients across the continent. Visit the Association website at www.eahad.org.

EAHAD EXECUTIVE COMMITTEE

Pier Mannuccio Mannucci, President
Jan Asterman, Vice-President
Philippe de Moerloose, Secretary
Christopher A. Ludlam, Treasurer
Gerry Dolan, Company Secretary
Kathelijn Fischer
Christine Harrington
Cedric Hermans
Johannes Oldenburg
Elena Santagostino
Jerzy Windyga
**SATELLITE SYMPOSIUM - Haemophilia with inhibitors: current state and future options**
**NOVO NORDISK**
**CHAIRS: M.G. Mazzucconi (Italy), P.M. Mannucci (Italy)**

**Introduction**
A. Obergfell (Switzerland)

Early treatment means rapid bleeding control
M. Morfini (Italy)

The importance of treatment optimization in children
E. Santagostino (Italy)

Current management of ITI
M.E. Mancuso (Italy)

Future of haemostasis in inhibitor patients: beyond current treatment
S.E. Bjørn (Novo Nordisk, Denmark)

**Discussion and conclusions**

---

**SATELLITE SYMPOSIUM - A natural pathway to longer lasting haemophilia therapies**
**SWEDISH ORPHAN BIOVITRUM AND BIOPEN IDEC HEMOPHILIA**

**CHAIRMAN AND CO-CHAIR: J. Astermark (Sweden), S. James (Sweden)**

A new age in haemophilia management

- Chairmen introduction
- Extending treatment through life and disease
  M. Makris (UK)
Fc fusion technology: a new approach for drug development in haemophilia

- Fc fusion technology
  P. Lind (Sweden)

- Assays – A technical overview
  J.M. Sommer (USA)

Longer lasting coagulation factors

- Clinical investigation of rFVIIIfc – a longer lasting coagulation factor VIII
  R. Klamroth (Germany)

- Individualized treatment - Coagulation factor pharmacokinetics and implications for treatment
  J. Pasi (UK)

Questions and panel discussion

**09.30-10.30  SCIENTIFIC SESSION 1**

**CHAIRS:** P.M. Mannucci (Italy), J. Astermark (Sweden)

The European Haemophilia Safety Surveillance System (EUHASS)
M. Makris (UK)

EAHAD working parties:

- IPD meta-analysis to investigate risk factors for inhibitor development
  A. Iorio (Italy)

- EAHAD working party on mutation databases
  C. Ludlam (UK)

- EAHAD working party on factor VIII assay discrepancies
  J. Oldenburg (Germany)

- EAHAD working party on epidemiology and management of rare bleeding disorders
  F. Peyvandi (Italy)

**10.30-11.00  BREAK**

**11.00-12.00  Other studies:**

- The SIPPET study: rationale and current state
  P.M. Mannucci (Italy)

- Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe haemophilia A: the RODIN study
  M. van den Berg (the Netherlands)

- European Haemophilia Therapy Standardization Board (EHTSB) and the Age-related Developments And Comorbidities in haemophilia (ADVANCE) group
  G. Dolan (UK)

- European initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study
  E. Santagostino (Italy)

**12.00-12.30  BREAK**

**12.30-14.00  LUNCH SATellite SYMPosium - Prophylaxis for life?**

**BAYER**

**CHAIRMAN and CO-CHAIR:** J. Astermark (Sweden), M. Morfini (Italy)

**Welcome**
J. Astermark (Sweden)

**Interactive case discussions:**

- Personalized prophylaxis: a “good companion” for life
  C. Santoro (Italy)

- Obstacles to treatment: overcoming inhibitors in prophylaxis
  P.A. Holme (Norway)

**Current clinical evidence**
R. Klamroth (Germany)

**Pharmacokinetics – are there differences between children and adults?**
S. Björkman (Sweden)

**Discussion and conclusion**
J. Astermark (Sweden), M. Morfini (Italy)

**14.00-14.30  BREAK**

**14.30-16.00  SCIENTIFIC SESSION 2**

**CHAIRS:** C.A. Ludlam (UK), J. Windyga (Poland)

New drugs for hepatitis C: their role in haemophilia and allied disorders
C. Colombo (Italy)

Outcome assessment in haemophilia therapy
V. Blanchette (Canada)

Ultrasound diagnosis of haemophilic arthropathy
C. Martinoli (Italy)

**16.00-16.30  BREAK**
16.30-17.30  **Scientific Session 3**
- **Chairs:** C. Hermans (Belgium), M. Makris (UK)
- Prophylaxis in rare bleeding disorders
  P. de Moerloose (Switzerland)
- Factor XIII deficiency: diagnostic and therapeutic issues
  H.P. Kohler (Switzerland)

17.30-18.30  **EAHAD General Assembly**

20.00-22.00  **Congress Dinner**

---

**Friday, February 24th**

8.30-10.30  **Scientific Session 4**
- **Chairs:** K. Fischer (the Netherlands), G. Dolan (UK)
- Tranexamic acid: the haemostatic drug of choice
  M. Levi (the Netherlands)
- Global coagulation tests: their role in haemophilia and acquired coagulation disorders
  Y. Dargaud (France)
- The ITI Study: clinical implications
  C. Hay (UK)
- The use of the clinical trial design in haemophilia: methodological considerations
  A. Iorio (Italy)

10.30-11.00  **Break**

11.00-12.30  **Scientific Session 5**
- **Chairs:** W. Schramm (Germany), F. Peyvandi (Italy)
- EMA and FDA requirements for licensing new haemophilia products: do they truly provide answers on safety/efficacy?
  L. Aledort (USA), E. Santagostino (Italy), C. Male (Austria)

12.30-12.45  **Break**

---

12.45-14.15  **Lunch Session - Poster Viewing and Manning**
- **Coordinators:** J. Astermark (Sweden), E. Santagostino (Italy), J. Windyga (Poland)
- **Break**

14.15-14.30  **Break**

14.30-16.00  **Scientific Session 6**
- **Chairs:** J. Oldenburg (Germany), P. de Moerloose (Switzerland)
- VWF, angiodysplasia and endothelial progenitor cells: novel insights from basic science
  A.M. Randi (UK)
- The value of genotyping in predicting poor response to desmopressin in mild haemophilia and von Willebrand disease
  G. Castaman (Italy)
- Gene therapy trial in severe haemophilia B
  E. Tuddenham (UK)

---

**Conclusions and CME Questionnaire (for Italian Delegates Only)**

---

16.30-17.30  **Scientific Session 3**
- **Coordinators:** J. Astermark (Sweden), E. Santagostino (Italy), J. Windyga (Poland)

---

20.00-22.00  **Congress Dinner**
Pfizer Haemophilia is dedicated to improving the lives of haemophilia patients

A world leader in advanced therapies for haemophilia

Devoted to treatments you can trust

Long-standing commitment to the haemophilia community